Login to Your Account



Glenmark in-licenses APC cancer drug, building innovation portfolio

By Michael Fitzhugh
Staff Writer

Tuesday, June 20, 2017

SAN DIEGO – Glenmark Pharmaceuticals Inc. has struck a deal to license a small-molecule cancer candidate from APC Therapeutics Inc., gaining worldwide development and commercialization rights to a compound based on APC biology.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription